Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired |
gptkb:Alder_Bio_Pharmaceuticals
gptkb:Serono |
| gptkbp:employs |
over 5,000 people
|
| gptkbp:focuses_on |
reproductive health
endocrinology orthopedics urology gastroenterology |
| gptkbp:founded |
1950
|
| gptkbp:founder |
Fredrik Ferring
|
| gptkbp:global_presence |
gptkb:true
|
| gptkbp:has_partnerships_with |
biotechnology companies
healthcare providers various research institutions |
| gptkbp:has_product |
gptkb:Liraglutide
Vasopressin Desmopressin Fertility medications Recombinant human growth hormone |
| gptkbp:has_received |
numerous awards
recognition for innovation recognition for quality |
| gptkbp:has_research_center |
in North America
in Europe in Asia |
| gptkbp:headquartered_in |
gptkb:Saint-Prex
|
| gptkbp:headquarters |
gptkb:Saint-Prex,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ferring Pharmaceuticals
|
| gptkbp:is_a_member_of |
gptkb:EFPIA
gptkb:Ph_RMA ISPE |
| gptkbp:is_committed_to |
research and development
innovation sustainability corporate social responsibility patient access |
| gptkbp:is_involved_in |
clinical trials
patient advocacy market access strategies regulatory affairs |
| gptkbp:is_known_for |
high-quality standards
innovative therapies patient-centric approach |
| gptkbp:is_privately_held |
gptkb:true
|
| gptkbp:operates_in |
over 100 countries
global market |
| gptkbp:specializes_in |
biopharmaceuticals
|
| gptkbp:subsidiary |
Ferring International Center S. A.
Ferring Pharmaceuticals Inc. Ferring Pharmaceuticals Ltd. |
| gptkbp:bfsParent |
gptkb:Firmagon
|
| gptkbp:bfsLayer |
6
|